QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EU Marketing-Authorisation Procedures for Human Medicines

Test your understanding of the concepts covered by Centralised, National, Mutual Recognition and Decentralised Procedures Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which feature is shared by MRP and DCP but does not by itself indicate a centralised procedure?

A European Commission decision creates one Union authorisation An RMS and CMSs participate in a coordinated assessment The product has legal effect automatically in every EU Member State CHMP is always the initial assessing committee

Question 2 of 10 Why is it incorrect to describe an RMS assessment in an MRP or DCP as an 'EU approval'?

Because RMS assessments concern only manufacturing inspections Because the RMS is a coordinating national authority, and the resulting authorisations remain national Because only applicants, not authorities, may use the term approval Because MRP and DCP do not involve any scientific assessment

Question 3 of 10 Why should a regulatory professional distinguish the initial authorisation route from later variations, referrals or safety assessments?

Later procedures are never legally relevant A later procedure may affect the product without changing how its original marketing authorisation was established Only initial applications have procedure numbers A referral automatically converts every national authorisation into a centralised authorisation

Question 4 of 10 Which combination correctly describes the roles of the RMS and CMSs in an MRP or DCP?

The RMS issues the Union authorisation and CMSs provide only translations The RMS coordinates the assessment, while CMSs participate in reviewing it within the procedure The RMS is an EMA committee and CMSs are European Commission departments The RMS conducts a centralised assessment and CMSs replace the Commission decision

Question 5 of 10 Two medicines contain the same active substance, but one was authorised centrally and the other entered several Member States through DCP. What is the best regulatory conclusion?

They must have identical regulatory histories because the active substance is the same The DCP product is centrally authorised once more than one Member State participates The authorisation route must be determined from each product's formal regulatory record The centrally authorised product must have a better benefit-risk balance

Question 6 of 10 Which statement correctly describes the relationship between regulatory route and benefit-risk outcome?

A centralised route inherently indicates a more favourable benefit-risk balance A national route inherently indicates a less favourable benefit-risk balance The route determines the assessment architecture but does not itself predict whether the benefit-risk balance is favourable MRP and DCP do not require assessment of benefit-risk balance because they rely on coordination

Question 7 of 10 A regulatory report states that a product was 'approved by EMA.' What is the most precise corrective interpretation for a centrally authorised medicine?

EMA issues the final legally operative marketing-authorisation decision CHMP performs the scientific assessment and adopts an opinion, followed by a European Commission decision establishing the authorisation The RMS issues the authorisation after EMA confirms the assessment CMDh adopts the Union marketing-authorisation decision

Question 8 of 10 What is the most accurate interpretation of the statement that a national authorisation is not subject to a lower scientific standard than a centralised authorisation?

All national and centralised applications are assessed by exactly the same authority The routes differ mainly in legal architecture, authorities and territorial scope rather than by a simple high-versus-low scientific standard National authorities may approve products without evaluating benefit-risk balance Centralised applications are assessed only for quality, whereas national applications are assessed for all three quality, safety and efficacy elements

Question 9 of 10 Which finding most strongly supports classification of a procedure as an MRP rather than a DCP?

The procedure involves more than one Member State An RMS and CMSs are identified A national marketing authorisation and assessment already existed before recognition was sought elsewhere The product information is intended to be harmonised

Question 10 of 10 A regulatory professional finds a later variation procedure number in a product file. What can reasonably be concluded about the product's original authorisation route?

The later procedure number automatically proves that the product was centrally authorised The later procedure number replaces the original authorisation route The later procedure records a subsequent regulatory event and does not necessarily change the initial authorisation pathway The product must have been authorised through MRP because variations are national

Knowledge Assessment: EU Marketing-Authorisation Procedures for Human Medicines

Cookie Settings